12 October 2017

King & Wood Mallesons climbs the ladder in global law firm brand rankings

King & Wood Mallesons (KWM) has improved its overall position in the 2017 Acritas Global Elite Law Firm Brand Index, ranking 13th.

The ranking is based on interviews with over 1000 senior legal buyers across the world’s largest multinationals with revenues in excess of $1bn.

The index is made up of four core brand measures: awareness, favourability, consideration for multi-jurisdictional deals and for multi-jurisdictional litigation.

This year KWM ranked 8th for ‘Favourability,’ and 11th for ‘Awareness.

Commenting on the firm’s performance, KWM Global Chairman, Wang Junfeng said: "We are pleased to have seen an increase in our overall brand positioning and in particular our significant rise in favourability this year, increasing our ranking from 17th to 8th on this measure. This reaffirms that our focus on developing and enhancing our client relationships, as well as understanding what our clients value most, is having a positive impact."

Global Managing Partner, Sue Kench, added: "Our global brand presence and positioning is critical to our global strategy of being the #1 top tier international firm in Asia. We will continue our focus on deepening and broadening our capability in the areas our clients value most and improving the quality and consistency of client service across our global network."

Media Contact

Share on LinkedIn Share on Facebook Share on Twitter Share on Google+
    You might also be interested in

    The project is the first Tesla factory outside the US, and also thus far the largest foreign-invested manufacturing project in Shanghai.

    16 July 2018

    The successful completion of this high-profile transaction marks one of the most significant financings in China’s entertainment industry in the first half of 2018.

    13 July 2018

    KWM team is led by partners Xiao Jin, Xue Han, and Liu Cheng.

    10 July 2018

    King & Wood Mallesons’ cross-border team, advised Luye Pharma Hong Kong Limited (“Luye Pharma”) on its transaction signed with AstraZeneca relating to the sale and licence of the rights to Seroquel...

    09 May 2018

    Legal services for your business

    This publication has been downloaded from the King & Wood Mallesons website. It is provided only for your information and does not constitute legal or other advice on any specific matter. If you require or seek legal advice you should obtain such advice from your own lawyer, and should do so before taking, or refraining from taking, any action in reliance on this publication. If you have any questions, please contact King & Wood Mallesons. See www.kwm.com for more information.